A PILOT FEASIBILITY STUDY OF INTRACEREBRAL MICRODIALYSIS TO DETERMINE THE NEURO

脑内微透析确定神经元的试点可行性研究

• 批准号: 7603889
• 负责人: JANA PORTNOW
• 金额: $ 2.81万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603889
• 关键词: Anesthesia procedures; Biopsy; Brain Neoplasms; Catheters; Cerebral cortex; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Craniotomy; Dose; Feasibility Studies; Funding; Goals; Grant; Institution; Microdialysis; New Agents; Patients; Pharmaceutical Preparations; Phase; Plasma; Protocols documentation; Research; Research Personnel; Resources; Screening procedure; Source; System; Tumor Debulking; United States National Institutes of Health; chemotherapy; temozolomide; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a system for efficiently screening new agents for potential use in Phase I and II brain tumor clinical trials by directly determining if these drugs can cross the BBB in patients with brain tumors. The plan is to place a microdialysis catheter into either the tumor or adjacent cerebral cortex when a brain tumor patient undergoes a biopsy or debulking craniotomy. Once the patient has recovered from the anesthesia and is stable post-operatively, s/he will be given a dose of a systemic chemotherapy agent (in this feasibility study temozolomide, a drug already known to cross the BBB, will be used), and intracerebral microdialysis will be performed to determine if any of the drug is recovered in the dialysate, reflecting the degree to which the drug is able to penetrate the BBB. Drug levels in the brain tumor interstitium will be compared to levels in the plasma.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该方案的总体目的是开发一种系统，以有效筛选新的药物，以通过直接确定这些药物是否可以在脑肿瘤患者中越过BBB，以在I和II期脑肿瘤临床试验中潜在使用。该计划是在脑肿瘤患者进行活检或缓解颅骨切开术时，将微透析导管放入肿瘤或邻近的大脑皮层中。一旦患者从麻醉中康复并且在术后稳定，他/他将获得一定剂量的全身化学疗法剂（在此可行性研究中，替莫唑胺（一种已知已经越过BBB）的药物将被使用），并且将执行脑内微透析的脑力透析，以确定该药物是否能够恢复到该药物的渗透，以恢复该药物的渗透，该药物是否能够恢复过疾病，该药物是否在疾病中恢复了疾病。 BBB。将脑肿瘤间质的药物水平与血浆中的水平进行比较。